KDIGO Clinical Practice Guideline for Acute Kidney Injury
This guideline cites 2 of the 58 landmark trials in our Nephrology register.
- Issued by
- KDIGO
- Year
- 2012
- Source
- Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. Kidney Int Suppl. 2012;2(1):1–138.
Fourteen years on, the 2012 AKI guideline is still KDIGO's only published AKI document. It unified the RIFLE and AKIN definitions into the creatinine-and-urine-output staging that every trial since has used, and it built the prevention and management chapters — haemodynamic and glycaemic targets, the drugs not to give, contrast-associated AKI, and the timing, modality and dose of renal replacement therapy. Its successor, the KDIGO 2026 guideline on acute kidney injury and acute kidney disease (AKI/AKD), completed public review in May 2026 and is being finalised; until it appears, the 2012 text stands. Because most of the trials that now define AKI practice were published after 2012, they are listed in a separate section below rather than presented as evidence this guideline could have drawn on.
Intensity of renal replacement therapy2
- 2009RENALNephrology · AKI · RRT doseIn 1,508 critically ill patients with acute kidney injury, higher-intensity continuous renal-replacement therapy did not reduce mortality compared with lower-intensity therapy.OR 1.0095% CI 0.81-1.23Read →
- 2008ATNNephrology · AKI · RRT doseIn 1,124 critically ill patients with acute kidney injury, intensive renal-replacement therapy did not reduce mortality compared with less-intensive therapy.OR 1.0995% CI 0.86-1.40Read →
Published since the guideline7
- 2021AKIKI 2Nephrology · AKI · RRT timingIn 278 patients with AKI and no urgent indication, a more-delayed renal-replacement strategy did not improve survival and trended toward harm compared with a delayed strategy.HR 1.6595% CI 1.09-2.50Read →
- 2020STARRT-AKI CoreNephrology · AKI · RRT timingIn 3,019 critically ill patients with acute kidney injury, accelerated renal-replacement therapy did not reduce mortality and increased dialysis dependence compared with a standard strategy.RR 1.0095% CI 0.93-1.09Read →
- 2018PRESERVENephrology · AKI · Contrast-associated AKIIn 5,177 high-risk patients undergoing angiography, intravenous sodium bicarbonate or acetylcysteine did not reduce contrast-associated kidney outcomes compared with control.Read →
- 2017PrevAKINephrology · AKI · Care bundlesIn 276 high-risk cardiac-surgery patients identified by biomarkers, a KDIGO care bundle reduced acute kidney injury compared with standard care.55.1% vs 71.7%Read →
- 2017AMACINGNephrology · AKI · Contrast-associated AKIIn 660 patients with CKD undergoing contrast procedures, withholding prophylactic intravenous hydration was non-inferior for preventing contrast-associated AKI compared with hydration.2.6% vs 2.7%Read →
- 2016ELAINNephrology · AKI · RRT timingIn 231 critically ill patients with acute kidney injury, early renal-replacement therapy reduced 90-day mortality compared with delayed initiation.HR 0.6695% CI 0.45-0.97Read →
- 2016AKIKINephrology · AKI · RRT timingIn 620 critically ill patients with stage 3 AKI, an early renal-replacement strategy did not improve survival compared with a delayed strategy.48.5% vs 49.7%Read →
Cited landmark trials not yet in the register5
Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.
- 2000Ronco CVVH dose trial
Higher ultrafiltration dose improved survival — the trial the 2012 dose recommendation reacts to.
- 2006Hemodiafe
Intermittent haemodialysis vs. continuous therapy in ICU AKI: no survival difference.
- 2008VISEP
Hydroxyethyl starch increased AKI and need for dialysis in severe sepsis.
- 2011ACT
N-acetylcysteine did not prevent contrast-induced AKI.
- 2007REMEDIAL
Sodium bicarbonate plus N-acetylcysteine for contrast nephropathy prophylaxis.
Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.